Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38156935)

  • 1. Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study.
    Wang X; Wang J; Chu Y; Hao J
    J Cancer Res Ther; 2023 Dec; 19(6):1663-1668. PubMed ID: 38156935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
    Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
    Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
    BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
    Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
    Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
    Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
    Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
    Yang Y; Yang G; Li W; Hao X; Zhang S; Ai X; Lei S; Xu H; Wang Y
    Thorac Cancer; 2023 Nov; 14(33):3275-3281. PubMed ID: 37740599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
    Yang G; Xu H; Yang Y; Zhang S; Xu F; Hao X; Li J; Xing P; Hu X; Liu Y; Wang L; Lin L; Wang Z; Duan J; Wang J; Wang Y
    BMC Med; 2022 Aug; 20(1):277. PubMed ID: 36031613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
    Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
    J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.
    Huang Y; Zhao Y; Huang Y; Yang Y; Zhang Y; Hong S; Zhao H; Zhao S; Zhou T; Chen G; Zhou H; Ma Y; Zhou N; Zhang L; Fang W
    MedComm (2020); 2024 May; 5(5):e536. PubMed ID: 38685972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
    Mazieres J; Lafitte C; Ricordel C; Greillier L; Negre E; Zalcman G; Domblides C; Madelaine J; Bennouna J; Mascaux C; Moro-Sibilot D; Pinquie F; Cortot AB; Otto J; Cadranel J; Langlais A; Morin F; Westeel V; Besse B
    J Clin Oncol; 2022 Mar; 40(7):719-728. PubMed ID: 35073148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study.
    Zhang X; Li Z; Han L; Lv Z; Teng Y; Cui X; Zhou C; Wu H; Fang W; Xu L; Zhao S; Song C; Zheng Y; Gao T; Li M
    Onco Targets Ther; 2022; 15():1067-1078. PubMed ID: 36199295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrotinib in
    Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
    J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poziotinib in Non-Small-Cell Lung Cancer Harboring
    Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA
    J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.